Plenty of news to cover in my Monday morning Deals update. Some impressive fund raising and deals across vaccines, ADCs, protein degradation, and neuroscience. Congratulations to everyone involved. Let me know if I have missed any.
🔔 AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform.
đź”” Maxion Therapeutics, a Cambridge biotech firm developing treatments for inflammatory diseases, has closed a ÂŁ58m Series A round.
đź”” With its FDA-approved neurostimulator implant aimed at helping patients recover from stroke, MicroTransponder has raised $65 million in venture capital funding to expand its commercial reach.
🔔 Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate (ADC) linker platform.
đź”” TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases announced the closing of its ÂŁ25 million seed funding round.
đź”” Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid pain management drugs.
🔔 Artificial intelligence company Hologen AI has committed up to $430 million as part of a multifaceted agreement to help take MeiraGTx’s Parkinson’s disease gene therapy all the way to market.
🔔 Tech firm Clario is boosting its electronic clinical outcome assessment (eCOA) offerings by acquiring the neuroscience-focused eCOA business of WCG.
🔔 Alongside new steps in its therapeutic pipeline—and a new push into laboratory robotics—Insilico Medicine has raised $110 million to carry forward its artificial intelligence-powered drug design platforms.
đź”” Japan’s Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense oligonucleotide for a rare type of blood cancer.
đź”” Roche pads out obesity pipeline, paying Zealand Pharma $1.6B upfront to codevelop amylin asset
đź”” Seattle-based Curevo Vaccine, a privately-held clinical-stage biotech company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, announces the closing of a $110 million Series B round to advance development of amezosvatein, its vaccine for shingles.
===============
Newton Colmore is a specialist search firm and we connect exceptional engineering and scientific talent with impactful companies, globally.